Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Healthtrust
Novartis
Queensland Health
Johnson and Johnson
Federal Trade Commission
Fish and Richardson
Teva
Daiichi Sankyo
AstraZeneca

Generated: January 18, 2018

DrugPatentWatch Database Preview

Claims for Patent: 9,326,945

« Back to Dashboard

Summary for Patent: 9,326,945
Title:Apixaban formulations
Abstract: Compositions comprising crystalline apixaban particles having a D.sub.90 equal to or less than 89 .mu.m, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to for the treatment and/or prophylaxis of thromboembolic disorders.
Inventor(s): Patel; Jatin (West Windsor, NJ), Frost; Charles (Yardley, PA), Jia; Jingpin (Belle Mead, NJ), Vemavarapu; Chandra (Hillsborough, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ) Pfizer Inc. (New York, NY)
Application Number:13/579,796
Patent Claims: 1. A solid pharmaceutical composition comprising a therapeutically effective amount of crystalline apixaban particles and a pharmaceutically acceptable diluent or carrier, wherein the crystalline apixaban particles have a D.sub.90 equal to or less than about 89 .mu.m, and wherein at least 77 wt % of apixaban dissolves within 30 minutes in a pH 6.8 phosphate buffer containing 0.05% sodium lauryl sulfate.

2. The composition as defined in claim 1, wherein said composition comprises Form N-1 of apixaban.

3. The composition as defined in claim 1, wherein the D.sub.90 is equal to or less than 85 .mu.m.

4. The composition as defined in claim 1, wherein the D.sub.90 is equal to or less than 50 .mu.m.

5. The composition as defined in claim 1, wherein the D.sub.90 is equal to or less than 30 .mu.m.

6. The composition as defined in claim 1, wherein the D.sub.90 is equal to or less than 25 .mu.m.

7. The composition as defined in claim 1, further comprising: from 1% to 2% by weight of a surfactant.

8. The composition as defined in claim 7, wherein the surfactant is sodium lauryl sulfate.

9. The composition as defined in claim 1, wherein the pharmaceutical composition comprises from about 2.5 mg to about 5 mg of apixaban.

10. The composition as defined in claim 1, wherein the pharmaceutical composition comprises 2.5 mg of apixaban.

11. The composition as defined in claim 1, wherein the pharmaceutical composition comprises 5 mg of apixaban.

12. A solid pharmaceutical composition comprising a therapeutically effective amount of apixaban and a pharmaceutically acceptable diluent or carrier, wherein apixaban comprises crystalline apixaban particles, wherein the crystalline apixaban particles have a D.sub.90 equal to or less than about 89 .mu.m, and wherein, as measured using a USP Apparatus 2 at a paddle rotation speed of 75 rpm in 900 mL, of a dissolution medium at 37.degree. C., at least 77 wt % of apixaban in the pharmaceutical composition dissolves within 30 minutes in the dissolution medium, and the dissolution medium is 0.05 M sodium phosphate at a pH 6.8 containing 0.05% sodium lauryl sulfate.

13. The composition as defined in claim 12, wherein said composition comprises Form N-1 of apixaban.

14. The composition as defined in claim 12, wherein the D.sub.90 is equal to or less than 85 .mu.m.

15. The composition as defined in claim 12, wherein the D.sub.90 is equal to or less than 50 .mu.m.

16. The composition as defined in claim 12, wherein the D.sub.90 is equal to or less than 30 .mu.m.

17. The composition as defined in claim 12, wherein the D.sub.90 is equal to or less than 25 .mu.m.

18. The composition as defined in claim 12, further comprising: from 1% to 2% by weight of a surfactant.

19. The composition as defined in claim 18, wherein the surfactant is sodium lauryl sulfate.

20. The composition as defined in claim 12, wherein the pharmaceutical composition comprises from about 2.5 mg to about 5 mg of apixaban.

21. The composition as defined in claim 12, wherein the pharmaceutical composition comprises 2.5 mg of apixaban.

22. The composition as defined in claim 12, wherein the pharmaceutical composition comprises 5 mg of apixaban.

23. The composition as defined in claim 1, which is a tablet.

24. The composition as defined in claim 1, which is a capsule.

25. The composition as defined in claim 9, which is a tablet.

26. The composition as defined in claim 9, which is a capsule.

27. The composition as defined in claim 10, which is a tablet.

28. The composition as defined in claim 10, which is a capsule.

29. The composition as defined in claim 11, which is a tablet.

30. The composition as defined in claim 11, which is a capsule.

31. The composition as defined in claim 12, which is a tablet.

32. The composition as defined in claim 12, which is a capsule.

33. The composition as defined in claim 20, which is a tablet.

34. The composition as defined in claim 20, which is a capsule.

35. The composition as defined in claim 21, which is a tablet.

36. The composition as defined in claim 21, which is a capsule.

37. The composition as defined in claim 22, which is a tablet.

38. The composition as defined in claim 22, which is a capsule.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
McKesson
Accenture
Chinese Patent Office
Cerilliant
Cantor Fitzgerald
Fuji
Baxter
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot